University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Jody Lynn Baron, MD, PhD

Jody Lynn Baron, MD, PhD

Assistant Professor of Medicine, Department of Medicine (Infectious Diseases and Gastroenterology), UCSF

Cancer Center Program Memberships

Affiliate Member

Education

Swarthmore College, Swarthmore, PA, 1984-85 Rice University, Houston, Texas, BA, 1986, Biology & Philosophy
Yale University, MD 1993, Medicine
Yale University, PhD, 1994, Immunobiology
Stanford University, Residency, 1993-95 Internal Medicine
University of California, San Francisco, Clinical Fellow, 1995-96, Infectious Diseases
University of California, San Francisco, Fellowship, 1996-2000, Microbiol & Immunology
 


Professional Experience

  • 2000- 2002
    Assistant Research Scientist Departments of Microbiology and Immunology, and Internal Medicine, University of California, San Francisco
  • 2003-2
    Assistant Professor of Medicine Department of Medicine, Divisions of Infectious Diseases & Gastroenterology (UCSF Liver Center), University of California, San Francisco

Honors & Awards

  • 1982
    Westinghouse Science Talent Search honors group
  • 1992
    NIH Resident research award
  • 1986-1992
    NIH Fellowship -Medical Scientist Training Program Yale University
  • 1992
    Molecular Medicine Fellowship, University of California at San Francisco
  • 1997-2002
    Howard Hughes Postdoctoral Research Fellowship for Physicians
  • 1992
    UCSF Liver center pilot research grant
  • 2000-2002
    Pfizer Postdoctoral Fellowship in Infectious Diseases
  • 2003-2002
    Burroughs Wellcome Career Award in the Biomedical Sciences
  • 2002
    HHMI/BWF Leadership Coaching Award
  • 2002
    American Gastroenterological Association Fiterman Basic Science Award
  • 2004-2002
    American Liver Foundation Liver Scholar Award
  • 2005-2002
    Cancer Research Institute Investigator award
  • 2006-2011
    Burroughs Wellcome Fund Investigator in Pathogenesis of Infectious Disease
  • 2011-2013
    UCSF Program in Breakthrough Biomedical Research Award

Selected Publications

  1. Pierce AA, Duwaerts CC, Siao K, Mattis AN, Goodsell A, Baron JL, Maher JJ. CD18 deficiency improves liver injury in the MCD model of steatohepatitis. PLoS One. 2017; 12(9):e0183912.
    View on PubMed
  2. Duwaerts CC, Amin AM, Siao K, Her C, Fitch M, Beysen C, Turner SM, Goodsell A, Baron JL, Grenert JP, Cho SJ, Maher JJ. Specific Macronutrients Exert Unique Influences on the Adipose-Liver Axis to Promote Hepatic Steatosis in Mice. Cell Mol Gastroenterol Hepatol. 2017 Sep; 4(2):223-236.
    View on PubMed
  3. Yanagisawa H, Hashimoto M, Minagawa S, Takasaka N, Ma R, Moermans C, Ito S, Araya J, Budelsky A, Goodsell A, Baron JL, Nishimura SL. Role of IL-17A in murine models of COPD airway disease. Am J Physiol Lung Cell Mol Physiol. 2017 Jan 01; 312(1):L122-L130.
    View on PubMed
  4. Publicover J, Jespersen JM, Johnson AJ, Nishimura SL, Goodsell A, Wakil AE, Rosenthal P, Pai E, Avanesyan L, Cooper S, Baron JL. Liver capsule: Age-influenced hepatic immune priming determines HBV infection fate: Implications from mouse to man. Hepatology. 2016 Jan; 63(1):260.
    View on PubMed
  5. Hashimoto M, Yanagisawa H, Minagawa S, Sen D, Ma R, Murray LA, Tsui P, Lou J, Marks JD, Baron JL, Krummel MF, Nishimura SL. TGF-ß-Dependent Dendritic Cell Chemokinesis in Murine Models of Airway Disease. J Immunol. 2015 Aug 01; 195(3):1182-90.
    View on PubMed
  6. Brand OJ, Somanath S, Moermans C, Yanagisawa H, Hashimoto M, Cambier S, Markovics J, Bondesson AJ, Hill A, Jablons D, Wolters P, Lou J, Marks JD, Baron JL, Nishimura SL. Transforming Growth Factor-ß and Interleukin-1ß Signaling Pathways Converge on the Chemokine CCL20 Promoter. J Biol Chem. 2015 Jun 05; 290(23):14717-28.
    View on PubMed
  7. Hashimoto M, Yanagisawa H, Minagawa S, Sen D, Goodsell A, Ma R, Moermans C, McKnelly KJ, Baron JL, Krummel MF, Nishimura SL. A critical role for dendritic cells in the evolution of IL-1ß-mediated murine airway disease. J Immunol. 2015 Apr 15; 194(8):3962-9.
    View on PubMed
  8. Minagawa S, Lou J, Seed RI, Cormier A, Wu S, Cheng Y, Murray L, Tsui P, Connor J, Herbst R, Govaerts C, Barker T, Cambier S, Yanagisawa H, Goodsell A, Hashimoto M, Brand OJ, Cheng R, Ma R, McKnelly KJ, Wen W, Hill A, Jablons D, Wolters P, Kitamura H, Araya J, Barczak AJ, Erle DJ, Reichardt LF, Marks JD, Baron JL, Nishimura SL. Selective targeting of TGF-ß activation to treat fibroinflammatory airway disease. Sci Transl Med. 2014 Jun 18; 6(241):241ra79.
    View on PubMed
  9. Fomin ME, Zhou Y, Beyer AI, Publicover J, Baron JL, Muench MO. Production of factor VIII by human liver sinusoidal endothelial cells transplanted in immunodeficient uPA mice. PLoS One. 2013; 8(10):e77255.
    View on PubMed
  10. Publicover J, Gaggar A, Nishimura S, Van Horn CM, Goodsell A, Muench MO, Reinhardt RL, van Rooijen N, Wakil AE, Peters M, Cyster JG, Erle DJ, Rosenthal P, Cooper S, Baron JL. Age-dependent hepatic lymphoid organization directs successful immunity to hepatitis B. J Clin Invest. 2013 Sep; 123(9):3728-39.
    View on PubMed
  11. Zeissig S, Murata K, Sweet L, Publicover J, Hu Z, Kaser A, Bosse E, Iqbal J, Hussain MM, Balschun K, Röcken C, Arlt A, Günther R, Hampe J, Schreiber S, Baron JL, Moody DB, Liang TJ, Blumberg RS. Hepatitis B virus-induced lipid alterations contribute to natural killer T cell-dependent protective immunity. Nat Med. 2012 Jul; 18(7):1060-8.
    View on PubMed
  12. Kitamura H, Cambier S, Somanath S, Barker T, Minagawa S, Markovics J, Goodsell A, Publicover J, Reichardt L, Jablons D, Wolters P, Hill A, Marks JD, Lou J, Pittet JF, Gauldie J, Baron JL, Nishimura SL. Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin avß8-mediated activation of TGF-ß. J Clin Invest. 2011 Jul; 121(7):2863-75.
    View on PubMed
  13. Publicover J, Goodsell A, Nishimura S, Vilarinho S, Wang ZE, Avanesyan L, Spolski R, Leonard WJ, Cooper S, Baron JL. IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B. J Clin Invest. 2011 Mar; 121(3):1154-62.
    View on PubMed
  14. Vilarinho S, Ogasawara K, Nishimura S, Lanier LL, Baron JL. Blockade of NKG2D on NKT cells prevents hepatitis and the acute immune response to hepatitis B virus. Proc Natl Acad Sci U S A. 2007 Nov 13; 104(46):18187-92.
    View on PubMed
  15. Stetson DB, Mohrs M, Reinhardt RL, Baron JL, Wang ZE, Gapin L, Kronenberg M, Locksley RM. Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function. J Exp Med. 2003 Oct 06; 198(7):1069-76.
    View on PubMed
  16. Matsuda JL, Gapin L, Baron JL, Sidobre S, Stetson DB, Mohrs M, Locksley RM, Kronenberg M. Mouse V alpha 14i natural killer T cells are resistant to cytokine polarization in vivo. Proc Natl Acad Sci U S A. 2003 Jul 08; 100(14):8395-400.
    View on PubMed
  17. Mu D, Cambier S, Fjellbirkeland L, Baron JL, Munger JS, Kawakatsu H, Sheppard D, Broaddus VC, Nishimura SL. The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1. J Cell Biol. 2002 Apr 29; 157(3):493-507.
    View on PubMed
  18. Baron JL, Gardiner L, Nishimura S, Shinkai K, Locksley R, Ganem D. Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection. Immunity. 2002 Apr; 16(4):583-94.
    View on PubMed
  19. Cerwenka A, Baron JL, Lanier LL. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci U S A. 2001 Sep 25; 98(20):11521-6.
    View on PubMed

Go to UCSF Profiles, powered by CTSI